ClinicalTrials.gg
CompletedNCT03929666Updated Nov 4, 2026Results posted

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Phase 2 interventional study of ZW25 (Zanidatamab) and Capecitabine in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer, sponsored by Jazz Pharmaceuticals. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Updated Nov 4, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing cisplatin in Biliary Tract Neoplasms — 7 open to participants now, 10 under way, 2 of them phase 3. Cisplatin · Biliary Tract Neoplasms.

Enrollment
10th of 28
74 · median 50
Started
2019
with 3 others
Phase 2
15 of 28
3 open now
Registered
15th of 28
by date

Among the 28 studies testing cisplatin in Biliary Tract Neoplasms, this one is the 10th largest by enrollment, is one of 4 that started in 2019, is one of 15 in phase 2, and was the 15th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

7 of the 28 studies testing cisplatin in Biliary Tract Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing cisplatin in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).

Read the detailed description

Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the recommended dosage (RD) of ZW25 when administered in combination with each of these multi-agent chemotherapy regimens. Then, Part 2 of the study will evaluate the anti-tumor activity of ZW25 plus combination chemotherapy in HER2-expressing GEA, BTC, and CRC.

03

Conditions studied

  • HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Keywords

  • HER2
  • Bispecific antibody
  • Biparatopic antibody
  • Immunotherapy
  • Gastric cancers
  • Esophageal cancers
  • Gastroesophageal junction (GEJ) cancers
  • Chemotherapy
  • FP
  • mFOLFOX6
  • Capecitabine
  • Cisplatin
  • 5-FU
  • Leucovorin (folinic acid)
  • Oxaliplatin
  • XELOX
  • Gastrointestinal cancers
  • Gastroesophageal adenocarcinoma
  • Biliary tract cancer
  • Colorectal cancer
  • Intrahepatic cholangiocarcinoma
  • Extrahepatic cholangiocarcinoma
  • Gall bladder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease diagnosis:

    • Part 1:
    • GEA: Unresectable, locally advanced, recurrent or -expressing GEA (IHC 3+ or 2+ with or without gene amplification based upon local assessment or central assessment)
    • BTC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing BTC (including intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], or gallbladder cancer [GBC]) (IHC 3+ with or without gene amplification; or IHC 0, 1+ or 2+ with gene amplification, based upon central assessment)
    • CRC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing CRC (IHC 3+ with or without gene amplification; or IHC 0, 1+ or 2+ with gene amplification, based upon central assessment). Patients will be required to be extended RAS (KRAS and NRAS) and BRAF wild-type based upon central assessment.
    • Part 2:
    • GEA: Unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA (IHC 3+, or IHC 2+ and FISH+ by central assessment)
    • BTC: Same as Part 1
    • CRC: Same as Part 1
  • Tumor measurements as per (RECIST) version 1.1:

    • Part 1: Measurable or non-
    • Part 2: Measurable disease
  • An (ECOG) Performance Status score of 0 or 1
  • Adequate organ function
  • Adequate cardiac left ventricular function, as defined by a >/= institutional standard of normal

Exclusion criteria

Exclusion:

  • Prior treatment with a -targeted agent
  • Prior systemic anti-cancer therapy (including products) except prior /neoadjuvant therapy, which must be completed at least 6 months prior to first study treatment dosing. For subjects with BTC and CRC the following additional exceptions apply:

    • BTC: patients may have started therapy for advanced disease but may not have received more than one cycle of any standard gemcitabine-based chemotherapy regimen.
    • CRC: patients may have started therapy for advanced disease but may not have received more than one cycle of 5-FU-based chemotherapy (\< 1 month of therapy).
  • Patients with certain to bevacizumab cannot be enrolled on the mFOLFOX6-2 with bevacizumab arm.
  • Palliative radiotherapy is allowed if completed at least 2 weeks prior to first study treatment dosing
  • Untreated known (patients with treated brain metastases who are off , off antiseizure medications, and stable for at least 1 month at the time of screening are eligible)
  • cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF). Patients with known myocardial infarction or unstable angina within 6 months prior to randomization are also excluded.
  • Fridericia (QTcF) > 470 ms. For patients with longer QTcF on initial (ECG), follow-up ECG may be performed in triplicate to determine eligibility
  • Peripheral neuropathy > Grade 1 per v5.0
  • Clinically significant interstitial lung disease
  • Prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • Active or infection or infection with (HIV)-1 or HIV-2 (Exception: patients with well controlled HIV [e.g., > 350/mm3 and undetectable viral load] are eligible)
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    ZW25 + FP

    ZW25 plus fluorouracil (5-FU) and cisplatin

    Drug: ZW25 (Zanidatamab) · Drug: Cisplatin · Drug: Fluorouracil

  • Experimental
    ZW25 + mFOLFOX6

    ZW25 plus 5-FU, leucovorin, and oxaliplatin

    Drug: ZW25 (Zanidatamab) · Drug: Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin

  • Experimental
    ZW25 + XELOX

    ZW25 plus capecitabine and oxaliplatin

    Drug: ZW25 (Zanidatamab) · Drug: Capecitabine · Drug: Oxaliplatin

  • Experimental
    ZW25 + mFOLFOX6 with bevacizumab

    ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab

    Drug: ZW25 (Zanidatamab) · Drug: Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin · Drug: Bevacizumab

  • Experimental
    ZW25 + CisGem

    ZW25 plus cisplatin and gemcitabine

    Drug: Cisplatin · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)

    DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen.

    Time frame: Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)

  2. Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)

    AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).

    Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months

  3. Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)

    Grades of laboratory abnormalities were defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months

  4. Confirmed Objective Response Rate (ORR) (Parts 1 and 2)

    Number of participants who achieved a confirmed best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months

Secondary outcomes

  1. Disease Control Rate (Parts 1 and 2)

    Number of participants who achieved a best response of CR, PR, or stable disease (SD) during treatment per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

    Time frame: From time from best response (CR, PR, SD) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months

  2. Duration of Response (Parts 1 and 2)

    Median duration of response (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

    Time frame: From time from the first objective response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months

  3. Clinical Benefit Rate (Parts 1 and 2)

    Number of participants with SD for ≥ 24 weeks or a confirmed, best overall response of CR or PR per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

    Time frame: From time from the response (SD ≥ 24 weeks, CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months

  4. Progression-free Survival (Parts 1 and 2)

    Median progression-free survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

    Time frame: From the time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), clinical progression, or death from any cause, whichever occurred first, up to approximately 68 months

  5. Overall Survival (Parts 1 and 2)

    Median overall survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

    Time frame: From the time from the date of first dose of study treatment until the date of death from any cause, up to approximately 68 months

  6. Incidence of Postbaseline Anti-drug Antibodies (ADAs) (Parts 1 and 2)

    Number of participants who develop postbaseline ADAs are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

    Time frame: Cycle 1 Day 1 up to 30 days after last dose, up to approximately 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)

  7. End of Infusion Concentration of ZW25 (Parts 1 and 2)

    Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.

    Time frame: Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)

  8. Maximum Serum Concentration of ZW25 (Parts 1 and 2)

    Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.

    Time frame: Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)

  9. Trough Concentration of ZW25 (Parts 1 and 2)

    Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.

    Time frame: Cycle 1, Day 15; Cycle 2, Days 1 and 15; Cycle 3, Days 1 and 15; Cycle 4, Day 1, and Cycle 6, Day 1 (for ZW25 combined with XELOX, FP, or CisGem, each cycle is 21 days; for ZW25 combined with FOLFOX6 with or without BEV, each cycle is 28 days)

  10. Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)

    Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).

    Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.

  11. Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)

    Number of participants who experienced a maximum severity of Grade 3 or higher postbaseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.

07

Results

Posted Nov 4, 2026

Participant flow

A total of 74 participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 20 clinic centers in 4 countries (United States, Canada, Chile, and South Korea).

Participant flow — Overall Study
MilestoneGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Started131111921567
Completed00000000
Not completed131111921567
Withdrew: Death97461710
Withdrew: Study termination by sponsor44511554
Withdrew: Withdrawal of consent00220303

Outcome measures

PrimaryNumber of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)

DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen.

Time frame:
Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)
Reported as:
Count of participants · Participants
Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)1101011
PrimaryNumber of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)

AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).

Time frame:
From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Participants With At Least 1 TEAE (Part 1)1376—2667
Participants With At Least 1 TEAE (Parts 1 and 2)131111921567
PrimaryNumber of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)

Grades of laboratory abnormalities were defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

Time frame:
From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)876201021
PrimaryConfirmed Objective Response Rate (ORR) (Parts 1 and 2)

Number of participants who achieved a confirmed best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Time frame:
From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
Reported as:
Count of participants · Participants
Confirmed Objective Response Rate (ORR) (Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Confirmed Objective Response Rate (ORR) (Parts 1 and 2)49982665
SecondaryDisease Control Rate (Parts 1 and 2)

Number of participants who achieved a best response of CR, PR, or stable disease (SD) during treatment per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

Time frame:
From time from best response (CR, PR, SD) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
Reported as:
Count of participants · Participants
Disease Control Rate (Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Disease Control Rate (Parts 1 and 2)7910921265
SecondaryDuration of Response (Parts 1 and 2)

Median duration of response (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

Time frame:
From time from the first objective response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
Reported as:
Median · months
Duration of Response (Parts 1 and 2)
monthsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Duration of Response (Parts 1 and 2)28.06 (10.64 to NA)18.66 (2.79 to NA)11.01 (4.14 to NA)10.41 (4.04 to NA)NA (6.83 to NA)13.26 (4.14 to NA)NA (6.77 to NA)NA (NA to NA)
SecondaryClinical Benefit Rate (Parts 1 and 2)

Number of participants with SD for ≥ 24 weeks or a confirmed, best overall response of CR or PR per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

Time frame:
From time from the response (SD ≥ 24 weeks, CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
Reported as:
Count of participants · Participants
Clinical Benefit Rate (Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Clinical Benefit Rate (Parts 1 and 2)491082965
SecondaryProgression-free Survival (Parts 1 and 2)

Median progression-free survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

Time frame:
From the time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), clinical progression, or death from any cause, whichever occurred first, up to approximately 68 months
Reported as:
Median · months
Progression-free Survival (Parts 1 and 2)
monthsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Progression-free Survival (Parts 1 and 2)12.02 (1.22 to NA)19.94 (4.11 to 40.28)11.76 (6.60 to 45.40)9.63 (2.66 to NA)NA (8.21 to NA)9.43 (2.60 to 27.83)NA (8.18 to NA)NA (NA to NA)
SecondaryOverall Survival (Parts 1 and 2)

Median overall survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

Time frame:
From the time from the date of first dose of study treatment until the date of death from any cause, up to approximately 68 months
Reported as:
Median · months
Overall Survival (Parts 1 and 2)
monthsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Overall Survival (Parts 1 and 2)23.62 (5.52 to NA)37.59 (15.21 to NA)NA (18.66 to NA)29.60 (21.42 to 39.36)NA (23.59 to NA)31.93 (8.77 to NA)NA (36.34 to NA)NA (NA to NA)
SecondaryIncidence of Postbaseline Anti-drug Antibodies (ADAs) (Parts 1 and 2)

Number of participants who develop postbaseline ADAs are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.

Time frame:
Cycle 1 Day 1 up to 30 days after last dose, up to approximately 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
Reported as:
Count of participants · Participants
Incidence of Postbaseline Anti-drug Antibodies (ADAs) (Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Participants positive for treatment-emergent ADA10000000
Participants positive for treatment-induced ADA10000000
Participants negative for treatment-emergent ADA10811921466
SecondaryEnd of Infusion Concentration of ZW25 (Parts 1 and 2)

Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.

Time frame:
Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
Reported as:
Mean · ug/mL
End of Infusion Concentration of ZW25 (Parts 1 and 2)
ug/mLGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
End of Infusion Concentration of ZW25 (Parts 1 and 2)365.65 ± 33.6422.71 ± 24.5514.39 ± 21.8631.95 ± 12.5545.41 ± 16.5562.24 ± 17.8466.48 ± 17.9473.66 ± 6.8
SecondaryMaximum Serum Concentration of ZW25 (Parts 1 and 2)

Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.

Time frame:
Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
Reported as:
Mean · ug/mL
Maximum Serum Concentration of ZW25 (Parts 1 and 2)
ug/mLGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Maximum Serum Concentration of ZW25 (Parts 1 and 2)378.05 ± 111.53433.13 ± 111.80524.45 ± 108.76635.59 ± 77.79549.07 ± 89.52570.33 ± 105.06471.23 ± 79.07474.48 ± 32.48
SecondaryTrough Concentration of ZW25 (Parts 1 and 2)

Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.

Time frame:
Cycle 1, Day 15; Cycle 2, Days 1 and 15; Cycle 3, Days 1 and 15; Cycle 4, Day 1, and Cycle 6, Day 1 (for ZW25 combined with XELOX, FP, or CisGem, each cycle is 21 days; for ZW25 combined with FOLFOX6 with or without BEV, each cycle is 28 days)
Reported as:
Mean · ug/mL
Trough Concentration of ZW25 (Parts 1 and 2)
ug/mLGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Cycle 1 Day 1561.88 ± 38.0469.04 ± 28.62————107.26 ± 53.2196.25 ± 26.60
Cycle 2 Day 1111.11 ± 42.5392.71 ± 29.4063.59 ± 35.8558.60 ± 23.3660.18 ± 20.54125.65 ± 178.31145.40 ± 54.09116.63 ± 43.97
Cycle 2 Day 15143.35 ± 34.01172.43 ± 152.82————182.69 ± 54.01166.75 ± 34.37
Cycle 3 Day 1—101.69 ± 55.7443.02 ± NA113.47 ± 23.37—108.64 ± 39.11186.38 ± 23.22198.75 ± 38.24
Cycle 3 Day 15—138.40 ± 50.25————231.80 ± 43.82191.97 ± 31.43
Cycle 4 Day 1156.95 ± 59.21168.40 ± 70.91121.60 ± 38.11120.06 ± 28.47120.67 ± 36.62133.18 ± 47.44212.81 ± 24.90213.50 ± 76.0
Cycle 6 Day 1219.18 ± 64.14184.13 ± 56.14157.94 ± 62.51147.10 ± 45.80138.80 ± 1.49163.41 ± 40.41199.64 ± 34.07185.04 ± 37.72
SecondaryNumber of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)

Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).

Time frame:
From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Participants With At Least 1 TEAE (Part 1)1376—2667
Participants With At Least 1 TEAE (Parts 1 and 2)131111921567
SecondaryNumber of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)

Number of participants who experienced a maximum severity of Grade 3 or higher postbaseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

Time frame:
From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
Reported as:
Count of participants · Participants
Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)
ParticipantsGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)876201021

Adverse events

Collected over Adverse events (AEs) were collected from the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GEA: 20 mg/kg ZW25 Q2W + mFOLFOX69/13 (69.2%)4/13 (30.8%)13/13 (100%)
GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX67/11 (63.6%)4/11 (36.4%)11/11 (100%)
GEA: 30 mg/kg ZW25 Q3W + XELOX4/11 (36.4%)4/11 (36.4%)11/11 (100%)
GEA: 1800/2400 mg ZW25 Q3W + XELOX6/9 (66.7%)3/9 (33.3%)9/9 (100%)
GEA: 30 mg/kg ZW25 Q3W + FP1/2 (50%)2/2 (100%)2/2 (100%)
BTC: 1800/2400 mg ZW25 Q3W + CISGEM7/15 (46.7%)7/15 (46.7%)15/15 (100%)
CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX61/6 (16.7%)1/6 (16.7%)6/6 (100%)
CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV0/7 (0%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
DiarrhoeaGastrointestinal disorders2/130/110/110/91/20/150/61/7
Bile duct stoneHepatobiliary disorders0/130/110/110/91/20/150/60/7
Acute kidney injuryRenal and urinary disorders2/130/110/110/91/20/151/61/7
HypokalaemiaMetabolism and nutrition disorders1/132/110/110/90/20/150/60/7
ColitisGastrointestinal disorders0/130/110/110/90/21/151/60/7
NauseaGastrointestinal disorders0/130/110/111/90/21/150/61/7
VomitingGastrointestinal disorders1/131/110/110/90/21/150/61/7
DehydrationMetabolism and nutrition disorders1/130/110/110/90/20/150/61/7
Atrial fibrillationCardiac disorders0/130/110/110/90/20/150/61/7
UrosepsisInfections and infestations0/130/110/110/90/20/150/61/7
Most frequent other events
Showing 10 of 179
Most frequent other events
EventGEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV
DiarrhoeaGastrointestinal disorders11/1311/1111/117/92/212/155/66/7
NauseaGastrointestinal disorders12/1310/118/117/92/24/154/64/7
Blood creatine increasedInvestigations2/130/110/110/92/22/151/60/7
Decreased appetiteMetabolism and nutrition disorders7/138/115/115/92/23/150/63/7
Peripheral sensory neuropathyNervous system disorders7/1310/117/117/90/25/155/64/7
FatigueGeneral disorders10/139/114/115/90/22/152/64/7
AnaemiaBlood and lymphatic system disorders7/135/113/112/90/211/152/60/7
VomitingGastrointestinal disorders9/136/112/113/90/24/152/61/7
ConstipationGastrointestinal disorders4/137/114/112/90/26/152/60/7
HypokalaemiaMetabolism and nutrition disorders8/135/112/111/90/21/150/60/7

Baseline characteristics

Baseline characteristics were assessed using the Safety Analysis Set.

Age, Continuous
Age, Continuous(years)GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEVTotal
Mean63.0 ± 8.8461.1 ± 15.9352.8 ± 10.7954.3 ± 13.8759.0 ± 064.0 ± 10.8451.0 ± 10.5558.1 ± 14.6258.8 ± 12.44
Sex: Female, Male
Sex: Female, Male(Participants)GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEVTotal
Female2122053116
Male1110972103658
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6GEA: 30 mg/kg ZW25 Q3W + XELOXGEA: 1800/2400 mg ZW25 Q3W + XELOXGEA: 30 mg/kg ZW25 Q3W + FPBTC: 1800/2400 mg ZW25 Q3W + CISGEMCRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEVTotal
White12853022133
Black or African American000000000
Asian12662134640
American Indian or Alaska Native000000000
Native Hawaiian or Other Pacific Islander000000000
Not Reported000000000
Unknown010000001
08

Study locations

23 sites
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • The Cancer and Hematology Centers
    Grand Rapids, Michigan 49503, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G 2C1, Canada
  • Centro de Investigacion Clinica SAGA
    Santiago, 7500653, Chile
  • Icegclinic Research & Care
    Santiago, 8241479, Chile
  • CECIM Biocinetic
    Santiago, 8320000, Chile
  • Centro Internacional de Estudios Clínicos
    Santiago, 8420383, Chile
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Pusan National University
    Busan, 49241, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
09

References and documents

Publications

  • Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang YK, Kim JH, Lee KW, Lin B, Mehta R, Oh DY, Rha SY, Seol YM, Yang L, Ozog MA, Garfin PM, Ku G. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025 Jul;26(7):847-859. doi: 10.1016/S1470-2045(25)00287-6. Epub 2025 Jun 2. PubMed 40473445 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Aug 2025, 72 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2019
First posted
Apr 29, 2019
StartActual
Aug 22, 2019
Primary completionActual
Aug 30, 2025
CompletionActual
Aug 30, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Start date
Aug 29, 2019→Aug 22, 2019
Nov 4, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedIncidenceNumber of doseParticipants Reporting Dose-limiting toxicitiesToxicities (DLTs) (Part 1)Time frame: Up to 6 weeks → Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)
  • EditedIncidenceNumber of adverse eventsParticipants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)Time frame: Up to 11 months → From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
  • EditedConfirmed Objective response rateResponse Rate (ORR) (PartParts 1 and 2)Time frame: Up to 10 months → From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
  • ChangedBefore Incidence of lab abnormalities (Part 1)Now Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)Time frame: Up to 11 months → From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
Nov 4, 2026
Documents
Secondary outcomes
10 edited, 1 added, 2 removed
What changed in the outcomes
  • EditedDisease control rateControl Rate (Parts 1 and 2)Time frame: Up to 10 months → From time from best response (CR, PR, SD) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
  • EditedDuration of responseResponse (Parts 1 and 2)Time frame: Up to 2 years → From time from the first objective response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
  • EditedClinical benefit rateBenefit Rate (Parts 1 and 2)Time frame: Up to 2 years → From time from the response (SD ≥ 24 weeks, CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
  • EditedProgression-free survivalSurvival (Parts 1 and 2)Time frame: Up to 2 years → From the time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), clinical progression, or death from any cause, whichever occurred first, up to approximately 68 months
  • EditedOverall survivalSurvival (Parts 1 and 2)Time frame: Up to 2 years → From the time from the date of first dose of study treatment until the date of death from any cause, up to approximately 68 months
  • EditedIncidence of antiPostbaseline Anti-drug antibodiesAntibodies (ADAs) (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1 Day 1 up to 30 days after last dose, up to approximately 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
  • EditedEnd of infusion concentrationInfusion Concentration of ZW25 (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
  • EditedMaximum serum concentrationSerum Concentration of ZW25 (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
  • EditedTrough concentrationConcentration of ZW25 (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1, Day 15; Cycle 2, Days 1 and 15; Cycle 3, Days 1 and 15; Cycle 4, Day 1, and Cycle 6, Day 1 (for ZW25 combined with XELOX, FP, or CisGem, each cycle is 21 days; for ZW25 combined with FOLFOX6 with or without BEV, each cycle is 28 days)
  • EditedIncidenceNumber of adverse eventsParticipants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)Time frame: Up to 11 months → From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
  • AddedNumber of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
  • RemovedObjective response rate (ORR) (Part 1)Time frame: Up to 10 months
  • RemovedIncidence of lab abnormalities (Part 2)Time frame: Up to 11 months
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Start date Aug 29, 2019→Aug 22, 2019
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedIncidenceNumber of doseParticipants Reporting Dose-limiting toxicitiesToxicities (DLTs) (Part 1)Time frame: Up to 6 weeks → Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)
    • EditedIncidenceNumber of adverse eventsParticipants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)Time frame: Up to 11 months → From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
    • EditedConfirmed Objective response rateResponse Rate (ORR) (PartParts 1 and 2)Time frame: Up to 10 months → From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
    • ChangedBefore Incidence of lab abnormalities (Part 1)Now Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)Time frame: Up to 11 months → From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
    Secondary outcomes 10 edited, 1 added, 2 removed
    What changed in the outcomes
    • EditedDisease control rateControl Rate (Parts 1 and 2)Time frame: Up to 10 months → From time from best response (CR, PR, SD) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
    • EditedDuration of responseResponse (Parts 1 and 2)Time frame: Up to 2 years → From time from the first objective response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
    • EditedClinical benefit rateBenefit Rate (Parts 1 and 2)Time frame: Up to 2 years → From time from the response (SD ≥ 24 weeks, CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
    • EditedProgression-free survivalSurvival (Parts 1 and 2)Time frame: Up to 2 years → From the time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), clinical progression, or death from any cause, whichever occurred first, up to approximately 68 months
    • EditedOverall survivalSurvival (Parts 1 and 2)Time frame: Up to 2 years → From the time from the date of first dose of study treatment until the date of death from any cause, up to approximately 68 months
    • EditedIncidence of antiPostbaseline Anti-drug antibodiesAntibodies (ADAs) (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1 Day 1 up to 30 days after last dose, up to approximately 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
    • EditedEnd of infusion concentrationInfusion Concentration of ZW25 (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
    • EditedMaximum serum concentrationSerum Concentration of ZW25 (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
    • EditedTrough concentrationConcentration of ZW25 (Parts 1 and 2)Time frame: Up to 11 months → Cycle 1, Day 15; Cycle 2, Days 1 and 15; Cycle 3, Days 1 and 15; Cycle 4, Day 1, and Cycle 6, Day 1 (for ZW25 combined with XELOX, FP, or CisGem, each cycle is 21 days; for ZW25 combined with FOLFOX6 with or without BEV, each cycle is 28 days)
    • EditedIncidenceNumber of adverse eventsParticipants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)Time frame: Up to 11 months → From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
    • AddedNumber of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
    • RemovedObjective response rate (ORR) (Part 1)Time frame: Up to 10 months
    • RemovedIncidence of lab abnormalities (Part 2)Time frame: Up to 11 months
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03929666
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Aug 22, 2019
Primary completion
Aug 30, 2025
Completion
Aug 30, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Jazz Medical Director
study director · Jazz Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanidatamab · Cisplatin · Gemcitabine

Start the discussion